First healthy volunteers receive TRIV-573 doses in Triveni Bio’s Phase I trial
Triveni Bio’s lead programme, TRIV-509, is in Phase II trial for atopic dermatitis, with results expected by 2026-end.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance